Key Highlights
- Philips shares are trading up 2.28% at $27.54, against a previous close of $26.92.
- HyperVue Integrated is a fixed, single-room system for DeepOCT+NIRS imaging and X1-FFR physiology.
- Third-quarter results are due before the open on Nov. 3.
Philips (NYSE:PHG) shares are trading up 2.28% at $27.54, against a previous close of $26.92, after the company announced U.S. commercial availability of the HyperVue Integrated System. The shares are rising ahead of third-quarter results, which are due before the open on Nov. 3, with consensus looking for Earnings Per Share near $0.36 and Revenue of about $4.9 billion.
Royal Philips is an Amsterdam-headquartered health technology company founded in 1891 that has refocused from its lighting and consumer electronics roots on healthcare and personal well-being. It operates through Diagnosis & Treatment, which covers imaging, ultrasound and image-guided therapy, Connected Care, which covers patient monitoring, sleep and respiratory care and enterprise informatics, and Personal Health, which covers oral, personal and mother and child care. It employs about 66,000 people.
HyperVue Integrated Brings Imaging and Physiology Together
HyperVue Integrated is a new single-room, permanently installed configuration of the HyperVue Imaging System, built for DeepOCT+NIRS intravascular imaging and X1-FFR physiology assessment. Unlike the mobile configuration, which must be brought into the procedure room, powered and connected for every case, the integrated version stays in a dedicated interventional suite so the imaging capability is ready when clinicians need it.
X1-FFR is an FDA-cleared, AI-powered platform that derives fractional flow reserve from angiography, without a pressure wire or drug. Philips says it is the only FDA-cleared angiogram-derived FFR solution that uses a single angiographic view rather than two or three. The integrated system adds a table-mounted touchscreen so staff can control it at the bedside within the sterile field, along with controller updates intended to simplify setup.
The chief of cardiology at St. Francis Hospital & Heart Center said imaging technology in a high-volume cath lab needs to be readily available, simple to operate and easy to use at the point of care. By removing the need to move, connect and prepare a mobile system for each procedure, Philips says the integrated version reduces setup steps.
Broader Portfolio on Show at TCT
Philips is showcasing the system at TCT 2026 in San Diego, which runs from Oct. 31 to Nov. 3, alongside IntraSight Plus, its U.S.-available interventional guidance platform. IntraSight Plus combines IVUS, iFR and FFR physiology, co-registration, tri-registration and real-time device visualization to support assessment, treatment planning, device guidance and result verification in PCI.
Together the products give clinicians Options to assess coronary disease, plan and guide treatment and confirm procedural results with the imaging and physiology tools best suited to the patient and lesion.
Results Day and Valuation
The stock has risen on above-average Volume and outperformed a softer European healthcare sector. Investors are also recalling the second-quarter beat, which was followed by a 1.6% one-day gain. Medical technology peers have slid after recent guidance cuts, which keeps attention on Philips' outlook.
In 2025 Philips reported group sales of about EUR 17.8 billion, comparable sales growth of 2%, comparable order intake growth of 6% and income from operations of EUR 1,424 million. The Respironics recall continues to weigh on profitability and reputation. The shares pay a Dividend Yield of 3.47%, trade on a trailing price-to-earnings ratio of 21.14 and have a 52-week range of $23.62 to $33.44.
Product launches like HyperVue Integrated are small contributors to group results. The more important points on Nov. 3 will be margins, order intake and any change in the full-year outlook.






Please wait processing your request...